Neogen Co. (NASDAQ:NEOG) Shares Bought by Values First Advisors Inc.

Values First Advisors Inc. lifted its stake in shares of Neogen Co. (NASDAQ:NEOGFree Report) by 6.3% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 15,137 shares of the company’s stock after purchasing an additional 896 shares during the period. Values First Advisors Inc.’s holdings in Neogen were worth $304,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. Washington Trust Advisors Inc. lifted its stake in Neogen by 10.1% in the 4th quarter. Washington Trust Advisors Inc. now owns 11,966 shares of the company’s stock worth $241,000 after acquiring an additional 1,100 shares in the last quarter. Pacer Advisors Inc. boosted its stake in shares of Neogen by 77.3% during the 4th quarter. Pacer Advisors Inc. now owns 29,849 shares of the company’s stock valued at $600,000 after buying an additional 13,013 shares during the period. Raymond James Financial Services Advisors Inc. grew its holdings in shares of Neogen by 5.8% during the 4th quarter. Raymond James Financial Services Advisors Inc. now owns 12,900 shares of the company’s stock valued at $259,000 after acquiring an additional 711 shares in the last quarter. Legato Capital Management LLC increased its stake in shares of Neogen by 18.4% in the fourth quarter. Legato Capital Management LLC now owns 53,626 shares of the company’s stock worth $1,078,000 after acquiring an additional 8,330 shares during the last quarter. Finally, Handelsinvest Investeringsforvaltning purchased a new position in Neogen in the fourth quarter valued at about $368,000. Hedge funds and other institutional investors own 96.73% of the company’s stock.

Neogen Stock Performance

Shares of NASDAQ:NEOG traded up $0.32 during trading on Thursday, reaching $15.78. The stock had a trading volume of 1,275,580 shares, compared to its average volume of 1,877,231. The company has a quick ratio of 2.63, a current ratio of 3.54 and a debt-to-equity ratio of 0.28. The stock has a fifty day simple moving average of $16.32 and a two-hundred day simple moving average of $17.21. The firm has a market capitalization of $3.42 billion, a price-to-earnings ratio of 264.21 and a beta of 1.14. Neogen Co. has a 52 week low of $14.44 and a 52 week high of $24.09.

Neogen (NASDAQ:NEOGGet Free Report) last posted its quarterly earnings data on Tuesday, January 9th. The company reported $0.11 EPS for the quarter, topping analysts’ consensus estimates of $0.03 by $0.08. Neogen had a return on equity of 3.35% and a net margin of 1.28%. The business had revenue of $229.60 million for the quarter, compared to analyst estimates of $232.85 million. During the same period in the previous year, the company posted $0.15 earnings per share. The firm’s revenue for the quarter was down .2% on a year-over-year basis. As a group, analysts anticipate that Neogen Co. will post 0.54 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, Piper Sandler raised their price objective on shares of Neogen from $17.50 to $19.00 and gave the company a “neutral” rating in a research report on Thursday, January 18th.

Check Out Our Latest Stock Report on NEOG

About Neogen

(Free Report)

Neogen Corporation, together with its subsidiaries, engages in the development, manufacture, and marketing of various products and services dedicated to food and animal safety worldwide. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment offers diagnostic test kits and related products to detect dangerous and unintended substances in food and animal feed, including foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns; and AccuPoint Advanced rapid sanitation test to detect the presence of adenosine triphosphate, a chemical found in living cells, as well as provides genomics-based diagnostic technology and software systems that help testers to objectively analyze and store their results and perform analysis on the results from multiple locations over extended periods.

Featured Articles

Want to see what other hedge funds are holding NEOG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Neogen Co. (NASDAQ:NEOGFree Report).

Institutional Ownership by Quarter for Neogen (NASDAQ:NEOG)

Receive News & Ratings for Neogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neogen and related companies with MarketBeat.com's FREE daily email newsletter.